Future directions in stenting

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 1, 2010, Pages 1-6

  Finn, Aloke V ^a   Vorpahl, Marc ^b   Ladich, Elena ^b   Virmani, Renu ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; POLYMER; RAPAMYCIN; ZOTAROLIMUS; BIOMATERIAL;

ATHEROSCLEROSIS; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; HUMAN; REVASCULARIZATION; REVIEW; SAFETY; THERAPY EFFECT; TREATMENT INDICATION; AGED; ANIMAL; CHEMISTRY; CORONARY ARTERY DISEASE; EDITORIAL; MALE; MEDICAL TECHNOLOGY;

AGED, 80 AND OVER; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMEDICAL TECHNOLOGY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; MALE; POLYMERS;

EID: 77949512158     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.144     Document Type: Review

References (19)

1. Nakazawa G, Finn AV, Ladich E et al. Drug-eluting stent safety: findings from preclinical studies. Expert Rev. Cardiovasc. Ther. 6(10), 1379-1391 (2008).
2. Kubo T, Imanishi T, Kitabata H et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris a serial optical coherence tomography study. JACC: Cardiovasc. Imag. 1(4), 475-484 (2008).
3. Ahmed DD, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol. Allergy Clin. N. Am. 23(2), 205-219 (2003).
4. Leggat PA, Kedjarune U. Toxicity of methyl methacrylate in dentistry. Int. DentalJ. 53(3), 126-131 (2003).
5. Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev. Med. Devices 6(1), 33-42 (2009).
6. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52(5), 333-342 (2008).
7. Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus- eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119(5), 680-686 (2009).
8. Meredith IT, Ormiston J, Whitbourn R et al. Four-year clinical follow-up after i mplantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am. J. Cardiol. 100(8B), 56M-61M (2007).
9. Grube E, Hauptmann K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biogradable polymer coating. Eurointervention 1, 53-57 (2005).
10. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS), a randomised non-inferiority trial. Lancet. 372(9644), 1163-1173 (2008).
11. Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231-236 (2005). (Pubitemid 40966848)
12. Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol. 51(22), 2123-2129 (2008).
13. Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102(4), 399-404 (2000).
14. Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369(9576), 1869-1875 (2007).
15. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB), a prospective open-label trial. Lancet 371(9616), 899-907 (2008).
16. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB), 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897-910 (2009).
17. Nakazawa G, Granada JF, Alviar C et al. Anti-CD34 antibodies immobilized on the surface of sirolimus eluting stents enhance stent endothelialization. J. Am. Coll. Cardiol. Intervent. (2009) (In Press).
18. Srivatsa SS, Edwards WD, Boos CM et al. Histologic correlates of angiographic chronic total coronary artery occlusions: influence of occlusion duration on neovascular channel patterns and intimal plaque composition. J. Am. Coll. Cardiol. 29(5), 955-963 (1997).
19. Vorpahl M, Finn AF, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention (2010) (In Press)